Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, Yang H, Travins J, Murray S, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, Liu W, Yen KE.

Blood. 2015 Jan 8;125(2):296-303. doi: 10.1182/blood-2013-10-533604. Epub 2014 Nov 14.

2.

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR.

Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23.

3.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

4.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6. Review.

PMID:
24008432
5.

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE.

Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.

6.

Reevaluating the accelerated approval process for oncology drugs.

Wilson WH, Schenkein DP, Jernigan CL, Woodcock J, Schilsky RL.

Clin Cancer Res. 2013 Jun 1;19(11):2804-9. doi: 10.1158/1078-0432.CCR-13-0315. Epub 2013 Apr 3.

7.

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB.

Blood. 2012 Nov 29;120(23):4649-52. doi: 10.1182/blood-2012-06-438267. Epub 2012 Oct 16.

8.

Cancer-associated isocitrate dehydrogenase mutations.

Yen KE, Schenkein DP.

Oncologist. 2012;17(1):5-8. doi: 10.1634/theoncologist.2011-0429. Epub 2012 Jan 10. No abstract available.

9.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

10.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

11.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW.

J Exp Med. 2010 Feb 15;207(2):339-44. doi: 10.1084/jem.20092506. Epub 2010 Feb 8.

12.

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR.

J Thorac Oncol. 2008 Jan;3(1):68-74. doi: 10.1097/JTO.0b013e31815e8b88.

13.

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators.

Haematologica. 2006 Jul;91(7):929-34.

14.

Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP, Gilliland DG.

Blood. 2006 Aug 15;108(4):1339-45. Epub 2006 Apr 20.

15.

Antibody-based therapeutics: focus on prostate cancer.

Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH.

Cancer Metastasis Rev. 2005 Dec;24(4):521-37. Review.

PMID:
16408160
16.

Preclinical data with bortezomib in lung cancer.

Schenkein DP.

Clin Lung Cancer. 2005 Oct;7 Suppl 2:S49-55. Review.

PMID:
16250927
17.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.

18.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators.

Blood. 2005 Dec 1;106(12):3777-84. Epub 2005 Aug 11.

19.

Use of proteasome inhibition in the treatment of lung cancer.

Schenkein DP.

Clin Lung Cancer. 2004 Dec;6 Suppl 2:S89-96. Review.

PMID:
15638966
20.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2.

PMID:
19791425
21.

Targeted therapies for cancer 2004.

Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN.

Am J Clin Pathol. 2004 Oct;122(4):598-609. Review.

PMID:
15487459
22.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.

PMID:
15461622
23.

Pharmacogenomics.

Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.

Adv Anat Pathol. 2004 Jul;11(4):211-20. Review.

PMID:
15220824
24.

A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.

Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, Gorgun G, Relias V, Grodman H, Mahajan A, Foss FM.

Bone Marrow Transplant. 2004 May;33(9):881-9.

PMID:
14990986
25.

Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Petersen FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, Horowitz MM.

Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27.

26.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

27.

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP.

Blood. 2001 Oct 1;98(7):2059-64.

28.

Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease.

Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP, Foss FM.

Blood. 2001 Sep 1;98(5):1622-5.

29.

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.

Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, Perry J, Schenkein DP, List A, Mason JR, Bensinger W, Wheeler C, Freter C, Parker WRL, Emmanouilides C.

Bone Marrow Transplant. 2000 Sep;26(5):471-81.

30.

Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.

Schenkein DP, Koc Y, Alcindor T, Stadtmauer EA, Miller KB, Cooper BW, Partridge AH, Lazarus HM.

Biol Blood Marrow Transplant. 2000;6(4A):448-55.

PMID:
10975514
31.

Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.

Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, Snydman DR.

Biol Blood Marrow Transplant. 2000;6(1):44-9.

32.

Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.

Jabro G, Koc Y, Boyle T, Schenkein DP, Ravalese J, Wazer D, Miller KB.

Biol Blood Marrow Transplant. 1999;5(3):173-9.

33.

Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.

Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E.

Cancer. 1999 Feb 1;85(3):608-15. Review.

PMID:
10091734
34.

Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk.

Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller KB, Wong JB.

Clin Infect Dis. 1999 Feb;28(2):256-66.

PMID:
10064241
35.

Therapy of diffuse aggressive lymphomas.

Koc Y, Schenkein DP.

Cancer Treat Res. 1999;99:47-73. Review. No abstract available.

PMID:
9891863
36.

Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma.

Scadden DT, Schenkein DP, Bernstein Z, Luskey B, Doweiko J, Tulpule A, Levine AM.

Cancer. 1998 Dec 15;83(12):2580-7.

PMID:
9874466
37.

A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.

Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.

Biol Blood Marrow Transplant. 1997 Oct;3(4):210-6.

PMID:
9360783
38.

Neoplasms and transplantation - trading swords for plowshares.

Schenkein DP, Schwartz RS.

N Engl J Med. 1997 Mar 27;336(13):949-50. No abstract available.

PMID:
9070477
39.

Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma.

Przybylski GK, Goldman J, Ng VL, McGrath MS, Herndier BG, Schenkein DP, Monroe JG, Silberstein LE.

Blood. 1996 Dec 15;88(12):4620-9.

40.

High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma.

McCann JC, Kanteti R, Shilepsky B, Miller KB, Sweet M, Schenkein DP.

Biol Blood Marrow Transplant. 1996 Feb;2(1):37-43.

PMID:
9078353
41.

Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.

Frenette PS, Desforges JF, Schenkein DP, Rabson A, Slapack CA, Miller KB.

Am J Hematol. 1995 May;49(1):48-55.

PMID:
7741138
42.

Improved survival for patients with acute myelogenous leukemia.

Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH.

J Clin Oncol. 1995 Mar;13(3):560-9.

PMID:
7884416
43.

Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease.

Comenzo RL, Malachowski ME, Miller KB, Erban JK, Schenkein DP, Desforges JF, Berkman EM.

Transfusion. 1995 Jan;35(1):42-5.

PMID:
7998067
44.
45.

Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG)

Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, McGlave P, Lazarus HM.

Ann Intern Med. 1994 Jan 15;120(2):143-58. Review.

PMID:
8256974
46.

Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.

Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA, Berkman E, Rabson A.

Ann Hematol. 1994 Jan;68(1):15-20.

PMID:
8110873
47.

Hematology.

Miller KB, Schenkein DP.

JAMA. 1993 Jul 14;270(2):216-7. No abstract available.

PMID:
8315737
48.

Intravenous IgG for treatment of autoimmune disease.

Schenkein DP.

Hosp Pract (Off Ed). 1992 Oct 30;27(10A):29-36, 39-42 45 passim. Review. No abstract available.

PMID:
1400680
49.

Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma.

Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP, Desforges JF, Berkman EM.

Transfusion. 1992 Oct;32(8):729-31.

PMID:
1357788
50.

Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection.

Miller KB, Schenkein DP, Wasserman RL.

Clin Pharm. 1992 Jul;11(7):628-31. No abstract available.

PMID:
1617914

Supplemental Content

Loading ...
Support Center